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Abstract
The development of high-throughput sequencing technologies has transformed our
capacity to investigate the composition and dynamics of the microbial communities that
populate diverse habitats. Over the past decade, these advances have yielded an ava-
lanche of metagenomic data. The current stage of “van Leeuwenhoek”–like cataloguing, as
well as functional analyses, will likely accelerate as DNA and RNA sequencing, plus protein
and metabolic profiling capacities and computational tools, continue to improve. However, it
is time to consider: what’s next for microbiome research? The short pieces included here
briefly consider the challenges and opportunities awaiting microbiome research.
This Perspective is part of the “Where next?” Series.
Soon, we will enter an era when “the number of population genomes deposited in public data-
bases will dwarf those from isolates and single cells” (Gene Tyson). Clearly, as all authors noted
in the following, our focus will move from describing the composition of microbial communi-
ties to elucidating the principles that govern their assembly, dynamics, and functions. How will
such principles be discovered? Elhanan Borenstein proposes that a systems biology–based ap-
proach, particularly the development of mathematical and computational models of the inter-
actions between the specific community components, will be critical for understanding the
function and dynamics of microbiomes. Evolutionary biologists Howard Ochman and Andrew
Moeller want to decipher how microbial assemblies evolve but challenge us to also consider the
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that no competing interests exist.role of microbial communities in organismal evolution, and they make the exciting prediction
that microbes will be implicated in the evolution of eusociality and cooperation. Brett Finlay
underscores the need for deciphering the mechanistic bases—particularly the chemical/
metabolite signals—for interactions between members of microbial communities and their
hosts. He emphasizes how this knowledge will enable creation of new tools to manipulate
the microbiota, a key challenge for future investigation. Heidi Kong also encourages decipher-
ing the mechanisms that underlie associations between particular skin surfaces and disorders
and their respective microbiota. Jeffrey Gordon considers several intriguing opportunities
as well as challenges that manipulation of the gut microbiota presents for improved human
nutrition and health. Finally, Karen Nelson, Karim Dabbagh and Hamilton Smith suggest
that using synthetic genomes to create novel microbes or even synthetic microbiomes offers a
new way to engineer the microbiota. Overall, future microbiome research regarding the mole-
cules and mechanisms mediating interactions between members of microbial communities
and their hosts should lead to discovery of exciting new biology and transformative
therapeutics.
A Genome-Centric View of Microbiomes
Gene Tyson
Over the last decade, metagenomics has had a major impact on the way we study the micro-
biomes of environmental, clinical, and engineered habitats. Through shotgun sequencing of
DNA extracted from microbial communities, metagenomics bypasses traditional culture-de-
pendent biases and holds the promise of genome-based insights into the mostly uncharted mi-
crobial world. Until very recently, it has not been possible to obtain near complete genomes
from these data because limited sequencing throughput combined with the complexity of the
microbial communities under consideration precluded assembly, the only exception being low
complexity communities where genome reconstruction of dominant populations has been pos-
sible. Therefore, the primary way of extracting biologically meaningful information from large-
ly unassembled metagenomic datasets has been to use gene-centric approaches that explore the
distribution and abundance of genes and gene families between different environments. How-
ever, such analyses typically only use a tiny fraction of the entire dataset.
Recent advances in high-throughput sequencing and new tools for analyzing metagenomic
data are driving the rapid evolution of this field. One of the biggest changes is the increased
cost effectiveness and throughput of sequencing, which now makes it feasible to move beyond
single snapshot metagenomes to biologically replicated series of related metagenomes [1, 2].
Differential coverage–based approaches for analyzing metagenomic data are resulting in the en
masse recovery of tens to hundreds of population genomes from many different environments,
including rare populations from high complexity communities. In concert, lineage-specific sin-
gle-copy marker gene approaches are being developed that allow the completeness and con-
tamination of extracted population genomes to be rapidly assessed. When combined with
novel approaches to refine or close population genomes, biological inferences can be made
with increased confidence.
Single cell genomics also holds great promise for obtaining genomes from the uncultivated
microbial majority [3], although the technically demanding nature of the approach and need
for specialized equipment is likely to restrict access to this technology. By contrast, the technol-
ogy and tools necessary to obtain population genomes from metagenomic datasets is within
reach of most laboratories and likely to become widely adopted. It is reasonable to predict,
then, that the number of population genomes deposited in public databases will dwarf those
from isolates and single cells in the near future. More importantly, these recent developments
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nities that allows organism-based metabolic network models to be developed. For the first
time, we are able to examine the role of individual microbial populations in the context of the
rest of the community at the genome, transcriptome, and proteome level. The ability to pull
out most of the genomes in any given habitat (with the exception perhaps of soil), combined
with the relevant environmental metadata, means that we now have the key information need-
ed to understand and predict ecosystem functionality.
Systems Biology and Integrative Analysis of the Human
Microbiome
Elhanan Borenstein
The past decade has clearly been a golden age for microbiome research. Extensive efforts to
characterize the human microbiome, coupled with exciting advances in sequencing technolo-
gies and in computational techniques, have tremendously increased our knowledge about the
diversity of the microbiome and about its composition in health and in disease. Arguably, how-
ever, much of these recent efforts to map the microbiome and to identify shifts associated with
disease are conceptually no different from those described by Antony van Leeuwenhoek, the fa-
ther of microbiology, over three centuries ago. Indeed, van Leeuwenhoek’s meticulous depic-
tion of the “animals” he observed growing in the scurf of his teeth and his rigorous (albeit in
17th century standards) attempts to compare these animals to those he found on the teeth of
women, children, and elderly people, differ greatly in scale from our modern, sequencing-
based microbiome surveys but similarly focus on cataloging the components of the micro-
biome and on comparative analysis. Such detailed surveys are absolutely essential when study-
ing a complex system such as the human microbiome, yet this reductionist approach rarely
results in a principled understanding of the system under study. Rather, to truly reveal the un-
derlying principles that govern the human microbiome’s assembly, function, and dynamics ul-
timately requires going beyond characterizing the composition of the microbiome and calls for
the development of systems-level thinking and analysis.
The application of a systems biology approach to microbiome-derived metagenomic data is
therefore a natural and critical next step for microbiome research. The development of such a
Metagenomic Systems Biology framework is already under way, and studies that apply a
systems-based analysis to characterize the assembly, organization, and activity of the micro-
biome have recently been introduced [4, 5]. Following the traditional systems biology para-
digm, such studies emphasize the development of mathematical and computational models of
the microbiome with a focus on network-based analyses of the interactions between the micro-
biome’s components (be they genes or species) [6]. Mechanistic and phenomenological models
that could provide a predictive understanding of the microbiome’s function and dynamics are
an especially promising route, paving the way to rational microbiome design and personalized
microbiome-based intervention [7]. Yet, metagenomic systems biology is still in its infancy,
and much work is still required to overcome the many challenges involved in modeling a sys-
tem as multifaceted as the human microbiome and accounting for the complex interplay be-
tween the microbiome and its human host.
Importantly, systems thinking, analysis, and modeling are not limited to the study of inter-
actions among various components in the microbiome but should also be applied to studying
the links between different facets and measures of the microbiome. Clearly, much of the effort
in coming years is likely to focus on generating multiple types of ’omic data to characterize the
microbiome, including, most notably, metatranscriptomics, metaproteomics, and metametabo-
lomics [8]. Integrating these meta-omic datasets and, specifically, going beyond the
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links such data through a comprehensive mechanistic model of the microbiome is probably the
biggest challenge facing microbiome research in coming years.
Ultimately, however, just as systems biology research has revolutionized genomics, these ef-
forts to develop an integrative multi-meta-omic systems biology framework and to construct
systems-level predictive models of the microbiome are bound to revolutionize human micro-
biome research and our understanding of this magnificently complex ecosystem.
Microbiome Evolution
Howard Ochman and Andrew Moeller
The first high-throughput descriptions of microbial communities provided snapshots of the
bacterial diversity occurring at a single place at a single time (and typically recognized with a
single gene) but yielded little direct information about what these bacteria were doing, or even
if they were alive. We have approached the point where we can make nearly exhaustive surveys
of the bacteria inhabiting natural communities; but so far, little is known about their persis-
tence, their patterns of diversification or their episodes of adaptive evolution—basically, why
those particular bacteria that are there are there. Within communities, particular taxa rise and
fall in abundance, and the causes and consequences of these fluctuations are far from clear.
Soon, we will see long-term, in-depth analyses that employ single-cell genomics, instead of sim-
ply tallying those lumbering 16S rDNA sequences, to track the evolution and fate of individual
bacterial lineages within the complex environment of their hosts. Such studies will reveal how
the different evolutionary forces—mutation, selection, migration, and drift—shape the con-
tents, and ultimately, the metabolic capabilities, of microbial communities. Knowledge of these
processes will allow us to determine whether the presence and persistence of a bacterial lineage
in a microbiome are enabled by the host or by the other microbial members of the community.
Furthermore, it will become clear which lineages are functionally relevant to the community
and/or the host and which are simply bandwagon microbes.
When considering microbiomes and evolution, there are really two types of questions to
ponder. Although we need to understand how evolutionary forces operate in microbial assem-
blages, the greater mysteries concern those astonishing events through which microbial
communities and associations have swayed the course of organismal evolution. Microbes have
impelled some of the most profound changes in the evolution of life, and their vast numbersand
wide distribution imply the occurrence of several improbable events. Although evolution works
in ways that are difficult to predict, we anticipate that microbes will soon be implicated in the
evolution of eusociality and cooperation—hailed as one of the major transitions in evolution—
having arisen from demands to transfer those much-needed microbes among members of a
society.
Humans and Microbes
B. Brett Finlay
The past few years have seen a remarkable flurry of findings correlating the microbiota and
their impact on many diverse aspects of human biology. However, there are relatively few ex-
amples that define the mechanisms by which these interactions occur, and even fewer that then
exploit this knowledge. We do not even know yet what defines a healthy microbiota [9]. Most
studies of microbiota and disease have relied on community profiling or metagenomics, but
these have not been particularly useful in defining mechanisms involved. Two related areas of
research in the future will directly address these shortcomings.
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ies. A wonderful example of this is the demonstration that the short chain fatty acid (SCFA)
butyrate, produced by certain Clostridial species, interacts with G protein coupled receptors
(GPR41 and GPR43) to modulate regulatory T cell (Treg) production [10]. It is readily appar-
ent how such an approach can then be exploited to improve health or alter disease. However,
we know virtually nothing about most microbiota metabolites that are produced in vivo, even
though these are the key molecules that microbes use to converse with each other and the host.
The ability to grow particular microbes and even microbial communities in culture will enable
the identification of such molecules. This knowledge, combined with biological experiments in
improved animal models (such as human microbiota transplanted into mice expressing a
human immune system) will provide novel tools to study disruption of microbial communica-
tion between microbes and between microbes and the host.
The other major area of research that is critically needed is the ability to modulate particular
microbes within a microbiota community. Most studies find association with particular micro-
bial species, but this does not prove their involvement. Currently tools to modulate particular
microbes are unavailable, although vaccination and phage therapy have been proposed. New
methods are needed to tag particular species and/or identify molecules that can impact on spe-
cific species. The antibiotic pharmaceutical industry has vast collections of molecules that were
originally designed to kill microbes, and repurposing some of these molecules, combined with
other creative approaches, may provide such new tools. Complementing this will be new ways
to shift microbiota populations. Metabolomic knowledge, as well as the ability to grow defined
microbial populations in culture, will certainly provide clues about potential ways to do this.
The past few years have seen a remarkable demonstration of the role of microbiota in humans,
but what is now needed is a sound understanding of the molecules and mechanisms driving
this role and then to capitalize on this knowledge to improve health and decrease disease.
Varied Biogeography of Skin Microbial Communities in Health and
Disease
Heidi H. Kong
The microbial communities of human skin include signature taxa that are distinguishable from
other epithelial sites (oral mucosa, vaginal mucosa, gut), highlighting some of the unique fea-
tures of the skin microbiome [11]. Recent studies of multiple skin sites in healthy individuals
have demonstrated spatial diversity of skin microbial communities: topographically varied mi-
croenvironments of oily sites on the head and trunk; moist folds and creases; and dry broad flat
surfaces can harbor distinct bacterial communities. In contrast, skin fungal communities are
defined primarily by the predominance of the genus Malassezia over most of the sampled skin
surface, except for the feet, which harbor a more diverse fungal composition [12]. Metage-
nomics allows investigation into the functional potential of skin microbial communities and
demonstrates how species strains can vary biogeographically and individually, likely resulting
in functional differences contributing to health and disease [13].
The distinctive features of skin microbiota are also reflected in the compartmentalization of
host immune responses to local bacteria, e.g., topical association of commensal Staphylococcus
epidermidis can elicit IL-17A responses in skin but not in the gut [14]. Many host factors, in-
cluding physiology, age, metabolism, environment, exposures, and immunity, can have signifi-
cant effects on the resident skin microbial communities. Further research incorporating many
areas of science, e.g. other ’omics approaches, microbiology, molecular biology, and immunol-
ogy, will be essential to uncover the complexities of skin microbial communities and host–
microbial interactions.
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istically affect particular skin sites. For example, atopic dermatitis—commonly known as
eczema—exhibits site-selective skin eruptions, often affecting certain regions of patients’ arms
and legs. In skin microbiome studies of atopic dermatitis patients, the association of Staphylo-
coccus aureus and S. epidermidis at sites of disease flares raises additional questions about the
role of these bacteria in this inflammatory skin condition.
The excitement generated by microbiome studies has fueled tremendous interest in applying
knowledge resulting from skin microbiome studies. However, many genomics-based skin
microbiome studies to date are associative, and determining the underlying mechanisms re-
sponsible for these important observations about skin microbial communities will ultimately be
crucial. Premature efforts to manipulate host–microbial homeostasis could create unforeseen
adverse outcomes, in light of the potential pathogenicity of many commensal microbes and
ability of interspecies interactions to potentiate disease. Further investigations focusing on site-
specific skin–microbial interactions will lead to a better understanding of health and skin disor-
ders and subsequently identify potential microbiome-based interventions to ameliorate disease.
The Nexus of Food, Agriculture, Human Nutrition, and the Gut
Microbiome
Jeffrey I. Gordon
We are witnessing dramatic alterations in how and what we eat. Examples include the move
from traditional markets towards branded retail, processed foods with longer shelf lives, more
“ready-to-eat” items, the evolving dominance of snacking, and the decline in family dining
with the accompanying rise in individual eating. At the same time, we are experiencing rapid
expansion of our human population and great challenges related to sustainable agriculture.
The coalescence of these forces is creating a need for sustained innovation in identifying afford-
able new food sources and new highly nutritious foods.
Studies of the human gut microbiome are beginning to have a disruptive effect on current
views of human nutrition, and could catalyze efforts to integrate agricultural policies and prac-
tice, food production and distribution, and nutritional recommendations for consumers repre-
senting different ages, lifestyles, geographies, and states of health. Research platforms are being
implemented to determine the effects of existing foods, or those we envision creating in the fu-
ture, on the gut microbiota and its human hosts [15]. Deeper knowledge of the interrelation-
ship between the foods we consume and the properties of our gut microbial communities
should better inform the way we define our nutritional needs and status, thereby emphasizing
in new ways how foods are directly linked to human health. This knowledge will provide an
impetus to better characterize emerging food consumption patterns in countries representing
different cultural traditions, stages of economic development, and land/water resources. It will
create an opportunity to differentiate foods based on their effects on different consumer popu-
lations with distinct physiological, metabolic, and immune phenotypes, and different gut mi-
crobial community configurations. The results may herald a new epoch of precision nutrition,
where personal determination of health status (e.g., via smart phone-linked devices or novel
single-use diagnostics) drives increased focus on foods as a means for disease prevention as
well as treatment.
Agricultural, food, and pharmaceutical companies need to be engaged to effectively and re-
sponsibly apply this new knowledge. Government agencies should provide conceptual frame-
works for efficient and sensible regulatory schemes, and ways for construing intellectual
property that provide appropriate incentives for private investment while protecting the
public good.
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tured, naturally occurring members of the gut microbiota of human donors, who may or may
not be related to potential treatment recipients by biology or by shared living environments,
will focus attention on a number of issues; they include ownership of microbes (and concepts
of self) and the type of preclinical data packages and trial designs required for approval of
human studies. The possibility of “inoculating” malnourished infants and children with con-
sortia of cultured gut microbes to effect durable repair of their defective gut microbial commu-
nity maturation and restore healthy growth [16, 17] highlights the need to carefully address
issues of short- as well as long-term safety and efficacy and potential societal responses to inter-
ventions that produce enduring changes in human biology.
Underlying these efforts is a need to develop an educational outreach with a narrative and
vocabulary understandable to a broad and varied consumer population representing different
cultural traditions and widely ranging degrees of scientific literacy so that they can make in-
formed choices. It is critical that these scientific, social, cultural, ethical, regulatory, and educa-
tional challenges are addressed now, especially in the case of low-income countries where the
burden of disease is great and where application of discoveries related to the human gut micro-
biome are likely to have high impact.
Synthetic Biology and the Human Microbiome
Karen E. Nelson, Karim Dabbagh, Hamilton Smith
The field of human microbiome research has exploded since the first publication of a human
metagenomic study in 2006 [18]. Current estimates are that the microbes associated with the
human body include thousands of strains and species, and contribute significantly more genes
than our own (host) genomes. With the advent of next generation sequencing (NGS) and the
development of novel bioinformatics approaches, we have gained a deeper understanding of the
microbiome and its impact on health and disease in disorders of the skin (psoriasis, acne), the
gut (Crohn’s, colon cancer, colitis), the vaginal tract, and the oral cavity (caries). It is likely that
research on the human microbiome will continue to demonstrate other correlations such as a
relationship with the increased prevalence of autoimmune diseases, including Type 1 Diabetes.
While there have been several promising avenues for development of the microbiome as a
diagnostic (PCR-based approaches, for example, for the detection of pathogens), initial ap-
proaches to development as a therapeutic are relatively limited. Probiotics containing Lactoba-
cillus, Bifidobacterium, and Saccharomyces are available in pill form for treatment of traveler’s
diarrhea and antibiotic-induced diarrhea. Approaches for other intestinal diseases are much
cruder. The most popular example—Fecal Replacement Therapy—relies on the replacement of
gastrointestinal microbiota in diseased individuals with the fecal material from a “healthy” in-
dividual. Recent studies have suggested that this fecal population can be narrowed to a small
number of species, and one could expect that eventually the microbial products that are re-
sponsible for alleviating the condition will become a therapeutic product. Microbial replace-
ment therapies will likely become standard practice as we further understand the possibilities,
limitations, and implications of the microbiome.
The parallel development and expansion of the field of synthetic genomics creates novel op-
portunities for synthetic human microbiomes or their synthetic products, which can be used
for modulating human health. Synthetic biology has already proved successful in applications
to malarial therapeutics and for influenza vaccine production. Synthetic biology approaches
create an immense opportunity to develop modified species that can be introduced into the
human body and monitored (by use of a water mark or other biomarker). Probiotic or engi-
neered strains can be improved for efficiency—altering pathways that may result in increased
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One can imagine yeast, small eukaryotes, or bacteria producing bioactive compounds at disease
sites, such as the intestine or on skin, acting as a delivery system. They could also be used to
produce synthetic natural-product medicines [19]. Synthetic phages offer the promise of mod-
ulating populations of bacteria that have negative effects on human health [20].
While from a commercial standpoint, engineering live microorganisms creates novel intel-
lectual property and products differentiated from existing medicines and therapeutic ap-
proaches, one would expect that there will be significant challenges with merging the fields of
synthetic biology and human microbiome research from the regulatory perspective, especially
with respect to introducing altered species into the healthy human microbiome and natural en-
vironment in general. It is a timely topic, warranting further discussion and public awareness
as we explore using our natural microbial flora to further benefit our health.
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